Long-term Top 10 — Health Care — 18 Aug 2026
The ten as they stood on 18 Aug 2026. Scores, pillars and reasons are the ones recorded that day; nothing here is recomputed. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100.
The long-term score is a published weighted sum of percentile ranks, rebalanced on the first trading day of each month. A list is a published formula and its output, not a recommendation. Method version 1.
Get this list's changes by email
Who entered, who left, and the reason — with the score moves behind it.
Informational only — not financial advice. The daily email has not started yet — subscribing now puts you on the list for the first one. Unsubscribe in one click.
The ten
| # | Company | Sector | Score |
|---|---|---|---|
| 1 | Lilly (Eli) (LLY) Growth 97th (revenue growth year over year 49.6%, 3-year revenue CAGR 31.7%) and profitability 94th (return on equity 92.6%, operating margin 42.2%); weakest is valuation (10th, price to book 38.3, price to earnings 43.2). |
Health Care | 66.0 |
| 2 | ResMed (RMD) Financial health 88th (debt to equity 0.1, free cash flow margin 28.8%) and profitability 78th (operating margin 33.4%, return on equity 23.9%); weakest is long-term trend (35th, a "death cross" — its 50-day average is below its 200-day). |
Health Care | 65.3 |
| 3 | Amgen (AMGN) Profitability 87th (return on equity 89.3%, operating margin 30.3%) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is valuation (28th, price to book 20.4, price to earnings 25.8). |
Health Care | 62.9 |
| 4 | LIGAND PHARMACEUTICALS INC (LGND) Financial health 82nd (free cash flow margin 44.9%, debt to equity 0.4) and growth 77th (3-year revenue CAGR 11%); weakest is shareholder return (12th, consecutive years of dividend increases 1 year). |
Health Care | 61.7 |
| 5 | Johnson & Johnson (JNJ) Profitability 75th (return on equity 25.7%, operating margin 25.7%) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is valuation (30th, price to book 6.1, price to earnings 29.9). |
Health Care | 60.4 |
| 6 | Bristol Myers Squibb (BMY) Profitability 81st (return on equity 46.8%, operating margin 25.5%) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is growth (29th, revenue growth year over year 3.1%, 3-year revenue CAGR 1.4%). |
Health Care | 59.1 |
| 7 | NATIONAL HEALTHCARE CORP (NHC) Shareholder return 71st (consecutive years of dividend increases 5 years) and financial health 68th (debt to equity 0, free cash flow margin 9.4%); weakest is profitability (37th, operating margin 9.3%, return on equity 12.9%). |
Health Care | 57.8 |
| 8 | Royalty Pharma (RPRX) Shareholder return 71st (consecutive years of dividend increases 5 years) and profitability 70th (operating margin 59.6%, return on equity 12.3%); weakest is valuation (30th, price to earnings 41.1, price to book 3.4). |
Health Care | 57.2 |
| 9 | Quest Diagnostics (DGX) Shareholder return 71st (consecutive years of dividend increases 5 years) and long-term trend 70th (a "golden cross" — its 50-day average is above its 200-day); weakest is profitability (46th, operating margin 14.1%, return on equity 14.5%). |
Health Care | 56.2 |
| 10 | West Pharmaceutical Services (WST) Financial health 73rd (debt to equity 0.1, free cash flow margin 13.1%) and shareholder return 71st (consecutive years of dividend increases 5 years); weakest is valuation (19th, price to earnings 43.9, price to book 6.2). |
Health Care | 56.2 |
Entered on 18 Aug 2026
Lilly (Eli) (LLY) — Entered 18 Aug 2026: first selection for this list at rank 1, score 66.0.
ResMed (RMD) — Entered 18 Aug 2026: first selection for this list at rank 2, score 65.3.
Amgen (AMGN) — Entered 18 Aug 2026: first selection for this list at rank 3, score 62.9.
LIGAND PHARMACEUTICALS INC (LGND) — Entered 18 Aug 2026: first selection for this list at rank 4, score 61.7.
Johnson & Johnson (JNJ) — Entered 18 Aug 2026: first selection for this list at rank 5, score 60.4.
Bristol Myers Squibb (BMY) — Entered 18 Aug 2026: first selection for this list at rank 6, score 59.1.
NATIONAL HEALTHCARE CORP (NHC) — Entered 18 Aug 2026: first selection for this list at rank 7, score 57.8.
Royalty Pharma (RPRX) — Entered 18 Aug 2026: first selection for this list at rank 8, score 57.2.
Quest Diagnostics (DGX) — Entered 18 Aug 2026: first selection for this list at rank 9, score 56.2.
West Pharmaceutical Services (WST) — Entered 18 Aug 2026: first selection for this list at rank 10, score 56.2.
See every rebalance of this list →
Informational only — NOT financial advice.